| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -48.0 | -30.1 |
| EPS (diluted, $ a share) | $-0.79 | $-0.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MAZE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Maze Therapeutics, Inc.: key numbers
- Share price
- $33.90Close, Nov 16
- Market cap
- $1.85B
- Shares outstanding
- 54.68MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Maze Therapeutics, Inc.
All →Maze Therapeutics Financial Results
Maze Therapeutics reported third quarter 2026 financial results, ending the period with $477 million in cash and a projected runway into 2029. The company highlighted the completion of enrollment for its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, with data expected in early 2027. Net loss for the quarter was $38.4 million, driven by increased R&D expenses related to its clinical-stage pipeline.
- Term
- Q3 2026
“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort. HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”
Jason Coloma, Ph.D., chief executive officer of Maze
Maze Therapeutics CEO Jason V. Coloma Sells $1.04M of Stock
Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $30.09 to $31.05 a share (average $30.25) in 4 transactions, worth $1.04M in total on Nov 2, 2026. Shares held after the trade: 186,901 (-2.8%).
- Value
- $1.04M
- Shares
- 34,501
- Average price
- $30.25
- Role
- CEO
- Holding change
- -2.8%
- Trade date
- Nov 2, 2026
Maze Therapeutics Csbo Atul Dandekar Sells $241K of Stock
Atul Dandekar, Csbo, sold 7,500 shares of Maze Therapeutics, Inc. at $32.07 a share, worth $241K in total on Oct 29, 2026. Shares held after the trade: 32,316 (-18.8%).
- Value
- $241K
- Shares
- 7,500
- Price
- $32.07
- Role
- Csbo
- Holding change
- -18.8%
- Trade date
- Oct 29, 2026
Maze Therapeutics Other 8-K Filing
Maze Therapeutics entered into an exchange agreement with Frazier Life Sciences to exchange 2,776,007 shares of common stock for pre-funded warrants to purchase an equivalent number of shares. The transaction was conducted under Section 3(a)(9) of the Securities Act, which allows for the exchange of one class of securities for another with no new cash raised.
- Counterparty
- Frazier Life Sciences Public Fund, L.P.
Maze Therapeutics CEO Jason V. Coloma Sells $932K of Stock
Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $27.02 to $27.02 a share (average $27.02) in 2 transactions, worth $932K in total on Oct 1, 2026. Shares held after the trade: 191,447 (-14.3%).
- Value
- $932K
- Shares
- 34,501
- Average price
- $27.02
- Role
- CEO
- Holding change
- -14.3%
- Trade date
- Oct 1, 2026
Maze Therapeutics President, R&D & CMO Harold Bernstein Sells $435K of Stock
Harold Bernstein, President, R&D & CMO, sold 16,141 shares of Maze Therapeutics, Inc. at $26.93 a share, worth $435K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $435K
- Shares
- 16,141
- Price
- $26.93
- Role
- President, R&D & CMO
- Holding change
- -100.0%
- Trade date
- Oct 1, 2026